Vergelijking
Goserelin vs. Leuprorelin
Twee peptiden naast elkaar — identiteit, bewijsbasis, juridische status en bekende bijwerkingen.
Identiteit
Categorie
Onderzoek (overig)
Onderzoek (overig)
CAS-nr.
65807-02-5
53714-56-0
Molecuulmassa
1269.43 g/mol
1209.4 g/mol
Halfwaardetijd
4.2 h
3 h
Sequentie
pGlu-His-Trp-Ser-Tyr-D-Ser(tBu)-Leu-Arg-Pro-Azgly-NH2Pyr-His-Trp-Ser-Tyr-D-Leu-Leu-Arg-Pro-NHEtWerkingsmechanisme
Goserelin
As a GnRH agonist, goserelin binds to the GnRH receptors of the pituitary gland. Initial stimulation transiently raises luteinizing hormone (LH) and follicle-stimulating hormone (FSH). With continuous receptor occupancy, however, the receptors become desensitized and down-regulated, which reduces LH and FSH secretion and consequently the production of testosterone or estrogen. This mechanistic relationship is documented in the pharmacological literature.
Leuprorelin
Leuprorelin is a GnRH-receptor agonist. After binding to pituitary GnRH receptors, it first causes a transient surge in luteinizing hormone (LH) and follicle-stimulating hormone (FSH) release — the so-called flare. With continuous, non-pulsatile exposure the receptors are downregulated and desensitized, suppressing gonadotropin secretion and consequently lowering sex steroids (testosterone or estradiol) to low levels. This mechanism underlies the literature-described use in hormone-dependent conditions.
Bewijsbasis
Hoogste bewijs
Humane RCT
Humane RCT
Studies
4
4
waarvan bij mensen
4
4
Geregistreerde effecten
3
4
Openstaande tegenstrijdigheden
1
1
Gedocumenteerde bijwerkingen
2
3
Juridische status
Volledige vermeldingen
Frequently asked questions
- What is the difference between Goserelin and Leuprorelin?
- Goserelin is classified as "Onderzoek (overig)", while Leuprorelin is classified as "Onderzoek (overig)". Goserelin: Goserelin is a synthetic decapeptide and an agonist of gonadotropin-releasing hormone (GnRH). The medical literature describes it as a hormonal agent that suppresses the release of sex hormones through sustained receptor stimulation. Regulatory-approved indications include prostate cancer, advanced breast cancer, endometriosis, and endometrial thinning, among others. Leuprorelin: Leuprorelin (also leuprolide) is a synthetic nonapeptide analogue of gonadotropin-releasing hormone (GnRH/LHRH). It is an approved prescription medicine in several jurisdictions, including for advanced prostate cancer, endometriosis, uterine fibroids and central precocious puberty. This page neutrally summarizes the evidence base and legal status and is not a usage or dosing recommendation. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, Goserelin or Leuprorelin?
- The highest available evidence level is "Humane RCT" for Goserelin and "Humane RCT" for Leuprorelin. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of Goserelin and Leuprorelin in Germany and the United States?
- Duitsland: Goserelin — Op recept, Leuprorelin — Op recept. Verenigde Staten: Goserelin — Op recept, Leuprorelin — Op recept. These are factual summaries with source and review date on the individual pages.